KPV Oral (250 mcg capsule)
KPV (Lys-Pro-Val) is the terminal tripeptide of alpha-MSH. It has been studied only in cells and mice, and by mouth only in mice. The figures below are data from research sources and not instructions for use.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-10-31
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full KPV encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
In human intestinal cells, KPV enters the cell through PepT1 and reduces inflammatory signals (Dalmasso 2008). Colitis models in mice showed the same (Kannengiesser 2008).
Quick Start
- Range in the sources: 200–500 mcg a day.
- Evidence: community reports, with no clinical trial.
- Human data by mouth: none.
Range from research sources: KPV by mouth
Route: By mouth (per os) | Frequency: 1–2 times a day
| Week | Dose | Amount |
|---|---|---|
| Reported range | 200–500 mcg a day | — |
The range is published on peptidedosingprotocols.com as a community practice that is not a proven schedule in humans, and on peptidedosage.org (accessed 31/10/2026). peptidedosages.com has no oral schedule.
Related compounds
Protocol Overview
- KPV is small enough to be carried by PepT1, a protein of intestinal cells (Dalmasso 2008).
- In mouse colitis models, KPV in drinking water reduced inflammation. Xiao 2017 used nanoparticles, a different form from a plain capsule.
- No study of oral KPV in humans has been published.
Dosing Protocol
- The two sources state 200–500 mcg a day, in one or two intakes.
- No study defines a human oral dose or a duration of use.
Storage Instructions
- No published stability data were found for KPV capsules.
Important Notes
- The findings concern cells and mice. They have not been shown to carry over to humans.
- The amount given to mice does not translate directly into a human dose.
- The substance has not been approved by the FDA or the EMA.
Potential Benefits & Side Effects
Potential Benefits:
- In cells and mice: reduction of inflammatory markers in the intestine (Dalmasso 2008, Kannengiesser 2008)
- In mice: less inflammation with KPV in nanoparticles (Xiao 2017)
Potential Side Effects:
- The safety profile in humans is unknown.
- The sources mention mild gastrointestinal discomfort as community observations, with no trial data.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Immunosuppression with chronic use
KPV (α-MSH fragment) is strongly anti-inflammatory. Theoretical risk of reduced immune surveillance with long-term use. No clinical studies in humans.
📄 FEBS Lett 2005References
- Dalmasso G et al. Gastroenterology 2008 — Transport through PepT1 in cells and colitis in mice, KPV in drinking water.
View Source - Kannengiesser K et al. Inflamm Bowel Dis 2008 — Colitis models in mice.
View Source - Xiao B et al. Mol Ther 2017;25(7):1628-1640 — KPV in nanoparticles by mouth, in mice.
View Source - peptidedosingprotocols.com: KPV — Research source for the range. Accessed 31/10/2026.
View Source - peptidedosage.org: KPV — Second research source for the range. Accessed 31/10/2026.
View Source
External Sources & Regulatory Status
Regulatory Approvals
Research-only — α-MSH derivative
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →